Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics director Luke Evnin reported indirect open-market sales of 143,199 shares of Common Stock over two days. On July 6, 2026, entities associated with him sold 35,770 shares at a weighted average price of $0.32 per share. On July 7, 2026, they sold a further 107,429 shares at a weighted average price of $0.31 per share.
The trades were executed by multiple MPM-affiliated investment entities and carried out under a pre-established Rule 10b5-1 trading plan dated March 26, 2026. Following these transactions, those entities reported holding no shares of Werewolf Therapeutics.
RA Capital Management and affiliated funds filed Amendment No. 12 to their Schedule 13D reporting that their ownership in Werewolf Therapeutics common stock has fallen below the five percent threshold.
The reporting group now beneficially owns 1,985,541 shares, or 4.1% of the common stock, based on 48,596,817 shares outstanding as of May 1, 2026. Most of these shares, 1,853,646, are held by RA Capital Healthcare Fund, L.P., with an additional 131,895 shares held by RA Capital Nexus Fund II, L.P.
The funds recently executed several open market sales between June 29 and July 2, 2026, at weighted average prices ranging from $0.30 to $0.36 per share. The filing states the group ceased to be beneficial owners of more than five percent of Werewolf’s common stock on June 30, 2026, an important regulatory threshold for large shareholders.
Werewolf Therapeutics director Luke Evnin reported that affiliated investment entities sold 157,084 shares of Werewolf Therapeutics common stock in an open-market transaction at a weighted average price of $0.30 per share. The sales were executed on behalf of several MPM-managed entities under a Rule 10b5-1 trading plan dated March 26, 2026. Following the transactions, these entities together held 143,199 shares indirectly associated with Evnin, and he disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.